University of Cape Town
Rondebosch, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it
Tuberculosis
FollowWhat is new in Tuberculosis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 4-month regimen (2HERZ/2HRE)Phase 3 · NCT06727864
- 5 IU TB-PPDPhase 3 · NCT07152639
- 5 unit（U） ECPhase 3 · NCT07152639
- 5μg/ml EECPhase 3 · NCT07152639
- 6-month (2HERZ/4HRE)Phase 3 · NCT06727864
- 6EH³R³ZPhase 3 · NCT04260477
- 6EHRZPhase 3 · NCT04260477
- A1Phase 3 · NCT05081401
- A2aPhase 3 · NCT05081401
- A2bPhase 3 · NCT05081401
- A2cPhase 3 · NCT05081401
- A3Phase 3 · NCT05081401
- A4Phase 3 · NCT05081401
- A5Phase 3 · NCT05081401
- AspirinPhase 3 · NCT04145258
- Aspirin 150 mgPhase 3 · NCT05917340
- B-SOCPhase 3 · NCT05081401
- B1Phase 3 · NCT05081401
- BCGPhase 3 · NCT05947890 · NCT06050356 · NCT04975178
- Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+ZPhase 3 · NCT05081401
- BedaquilinePhase 3 · NCT06058299 · NCT07209761 · NCT05686356 · NCT06081361 · NCT06441006 · NCT05766267 · NCT06649721 · NCT03828201 · NCT06568484 · NCT05824871
- Bedaquiline (B)Phase 3 · NCT07129629 · NCT07076225 · NCT06905522 · NCT06114628
- Bedaquiline Oral TabletPhase 3 · NCT07486024
- BLMZPhase 3 · NCT07268664
- ClofaziminePhase 3 · NCT06081361 · NCT06649721 · NCT03828201
- ContezolidPhase 3 · NCT06811025 · NCT06081361 · NCT06811012
- CycloserinePhase 3 · NCT06081361
- DelamanidPhase 3 · NCT06081361 · NCT05766267 · NCT06649721 · NCT03828201
- Delamanid (DLM)Phase 3 · NCT05556746 · NCT03568383
- Dolutegravir 50mg TabPhase 3 · NCT06497465
- Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)Phase 3 · NCT06497465
- Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]Phase 3 · NCT06497465
- DoxycyclinePhase 3 · NCT06477185 · NCT06446245 · NCT05473520
- EthambutolPhase 3 · NCT07656012 · NCT04485156 · NCT06253715 · NCT06917495 · NCT06081361 · NCT05766267 · NCT07595042
- Ethambutol (E)Phase 3 · NCT07129629 · NCT05807399 · NCT07076225 · NCT06905522 · NCT07163143 · NCT06114628
- Expanded antimicrobial therapyPhase 3 · NCT07332325
- Extra 600mg of RifampicinPhase 3 · NCT07118696
- GamTBvacPhase 3 · NCT04975737
- High dose rifampicin (25mg/kg)Phase 3 · NCT05917340
- High-dose rifampicinPhase 3 · NCT04485156
- HREPhase 3 · NCT05917340
- HRZEPhase 3 · NCT07350174 · NCT06058299 · NCT05917340
- Hydrocortisone administrationPhase 3 · NCT07332325
- Intensified TBM treatmentPhase 3 · NCT04145258
- IsoniazidPhase 3 · NCT07656012 · NCT04485156 · NCT06253715 · NCT05807399 · NCT06917495 · NCT05766267 · NCT05383742 · NCT05122026 · NCT07708779 · NCT07124559 · NCT07595042 · NCT05917340
- Isoniazid (H)Phase 3 · NCT07129629 · NCT07076225 · NCT06905522 · NCT07163143 · NCT06114628
- Isoniazid (INH)Phase 3 · NCT05556746 · NCT03568383 · NCT05383742
- isoniazid and rifapentinePhase 3 · NCT06022146
- Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)Phase 3 · NCT03785106
- Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)Phase 3 · NCT03785106
- LevofloxacinPhase 3 · NCT04951986 · NCT06081361 · NCT06649721 · NCT03828201 · NCT06568484
- LinezolidPhase 3 · NCT06058299 · NCT07209761 · NCT06081361 · NCT07672405 · NCT06441006 · NCT06649721 · NCT03828201
- Linezolid (L)Phase 3 · NCT07076225 · NCT06905522 · NCT06114628
- M72/AS01E-4 Mycobacterium tuberculosis investigational vaccinePhase 3 · NCT06062238
- MDR-END Plus regimenPhase 3 · NCT07675954
- MetforminPhase 3 · NCT07136987
- MoxifloxacinPhase 3 · NCT07129629 · NCT06253715 · NCT05807399 · NCT07209761 · NCT06917495 · NCT06081361 · NCT06441006 · NCT05766267 · NCT07595042
- Moxifloxacin (M)Phase 3 · NCT06905522 · NCT06114628
- Moxifloxacin 400mgPhase 3 · NCT05917340
- MTBVACPhase 3 · NCT05947890 · NCT06997367 · NCT06272812 · NCT04975178
- Optimised dose rifampicinPhase 3 · NCT06057519
- Para-Aminosalicylic AcidPhase 3 · NCT06081361
- PrednisonePhase 3 · NCT04951986
- PretomanidPhase 3 · NCT06058299 · NCT07209761 · NCT05686356 · NCT07672405 · NCT06441006
- Pretomanid (Pa)Phase 3 · NCT05807399 · NCT06905522 · NCT06114628
- ProthionamidePhase 3 · NCT06081361
- PyrazinamidePhase 3 · NCT07656012 · NCT04485156 · NCT06253715 · NCT05807399 · NCT06917495 · NCT06081361 · NCT05766267 · NCT07595042 · NCT05917340
- Pyrazinamide (Z)Phase 3 · NCT07076225 · NCT06905522 · NCT07163143 · NCT06114628
- QuabodepistatPhase 3 · NCT07209761
- rifampicinPhase 3 · NCT05069688 · NCT07656012 · NCT04485156 · NCT05807399 · NCT05383742 · NCT05917340
- Rifampicin (R)Phase 3 · NCT07129629 · NCT07076225 · NCT06905522 · NCT07163143 · NCT06114628
- Rifampicin, Pyrazinamide, Ethambutol and IsoniazidPhase 3 · NCT04951986
- RifampinPhase 3 · NCT04951986 · NCT06253715 · NCT06917495 · NCT06701136 · NCT05766267 · NCT07595042 · NCT07600775
- Rifampin and IsoniazidPhase 3 · NCT06022146
- RifapentinePhase 3 · NCT06253715 · NCT06281834 · NCT05122026 · NCT07124559 · NCT07595042
- Sitafloxacin (S)Phase 3 · NCT07076225 · NCT06905522
- Standard dose rifampicinPhase 3 · NCT06057519
- Standard TB treatmentPhase 3 · NCT07136987
- Standard-of-care (SoC) treatmentPhase 3 · NCT07675954
- SteroidPhase 3 · NCT05917340
- SudapyridinePhase 3 · NCT06701136 · NCT05824871
- WHO TBM treatmentPhase 3 · NCT04145258
- Atorvastatin 40mgPhase 2/3 · NCT04147286 · NCT06199921
- Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelinesPhase 2/3 · NCT06441006
- Enhanced community-wide TB interventionPhase 2/3 · NCT06719193
- Isoniazid, rifapentinePhase 2/3 · NCT06568484
- levofloxacin and rifapentinePhase 2/3 · NCT06498414
- N-acetyl cysteinePhase 2/3 · NCT05686356
- RifabutinPhase 2/3 · NCT05766267
- RifafourPhase 2/3 · NCT05686356
- Rifampin and Isoniazid daily for 12 weeksPhase 2/3 · NCT03474029
- Rifampin daily for 16 weeksPhase 2/3 · NCT03474029
- rifampin double dosePhase 2/3 · NCT06498414
- rifampin standard armPhase 2/3 · NCT06498414
- Rifapentine and Isoniazid weekly for 12 weeksPhase 2/3 · NCT03474029
- Rifapentine daily for 6 weeksPhase 2/3 · NCT03474029
- Routine TB program activitiesPhase 2/3 · NCT06719193
- Standardized RegimenPhase 2/3 · NCT05401071
- SutezolidPhase 2/3 · NCT05686356
- 3-month BDCZ regimenPhase 2 · NCT07893444
- 4-month FDC-based regimenPhase 2 · NCT07893444
- Acetohydroxamic AcidPhase 2 · NCT07393438
- Adalimumab InjectionPhase 2 · NCT05590455
- Adjunctive corticosteroidPhase 2 · NCT06446245
- Alpibectir (GSK3729098)Phase 2 · NCT05807399
- Alpibectir 45 mg OD plus Ethionamide 250 mg ODPhase 2 · NCT06748937
- Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg ODPhase 2 · NCT06748937
- Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg ODPhase 2 · NCT06748937
- Anti Tuberculosis DrugPhase 2 · NCT06446245
- Atorvastatin 20 mgPhase 2 · NCT07303699
- Atorvastatin 20mgPhase 2 · NCT06199921
- Atorvastatin 40 mgPhase 2 · NCT07303699
- Atorvastatin 60 mgPhase 2 · NCT07303699
- Atorvastatin 60mgPhase 2 · NCT06199921
- BCG SiiPhase 2 · NCT06997367
- Bedaquiline (BDQ)Phase 2 · NCT05556746
- Bedaquiline, pretomanid and linezolidPhase 2 · NCT07525427
- Bedaquiline, pretomanid and TBD09Phase 2 · NCT07525427
- BPaLMZ RegimenPhase 2 · NCT07227779
- BTZ-043Phase 2 · NCT05807399 · NCT06114628
- BTZ-043 250 mg or 500 mgPhase 2 · NCT07773610
- Clofazimine (CFZ)Phase 2 · NCT05556746
- Delamanid (D)Phase 2 · NCT07129629 · NCT07170800 · NCT06114628
- Delpazolid (DZD)Phase 2 · NCT06114628
- Delpazolid (LCB01-0371)Phase 2 · NCT05807399
- Ethambutol (EMB)Phase 2 · NCT05556746 · NCT05383742
- EthionamidePhase 2 · NCT05807399
- Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamid (Z) Ethambutol (E)Phase 2 · NCT07303699
- Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)Phase 2 · NCT06199921
- GanfeborolePhase 2 · NCT07784894 · NCT06114628
- Ganfeborole (GSK3036656)Phase 2 · NCT05807399
- Ganfeborole 20 mgPhase 2 · NCT07773610
- HRPhase 2 · NCT06058299
- HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)Phase 2 · NCT07773610 · NCT07073638
- HRZE plus Alpe375Phase 2 · NCT07350174
- HRZE plus AlpE500Phase 2 · NCT07350174
- HRZE plus AlpE625Phase 2 · NCT07350174
- ID93 + GLA-SE vaccinePhase 2 · NCT06205589
- Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight basedPhase 2 · NCT06748937
- JDB0131 100mgPhase 2 · NCT07170800
- JDB0131 200mgPhase 2 · NCT07170800
- Linezolid (LZD)Phase 2 · NCT06811025 · NCT05383742 · NCT06811012
- Linezolid 600Mg TabPhase 2 · NCT07773610
- Linezolid arm (ZYVOXID®)Phase 2 · NCT05534750
- Pretomanid 200mgPhase 2 · NCT07773610
- Pyrazinamide (PZA)Phase 2 · NCT07129629 · NCT05556746 · NCT05383742
- Pyrazinamide and Hydroxychloroquine (AI-Optimised)Phase 2 · NCT07467252
- Quabodepistat (Q)Phase 2 · NCT06114628
- Quabodepistat (Q) 30 mgPhase 2 · NCT07773610
- RESP30TBPhase 2 · NCT07073638
- Rifampicin (RIF)Phase 2 · NCT05556746 · NCT05383742
- Rifapentine (RPT)Phase 2 · NCT06917495
- sorfequilinePhase 2 · NCT06058299 · NCT07672405
- Standard 6-month treatment regimenPhase 2 · NCT07893444
- Standard quadruple therapy armPhase 2 · NCT05534750
- Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)Phase 2 · NCT07467252
- TBAJ-587 50 mgPhase 2 · NCT07773610
- Tedizolid arm (SIVEXTRO®)Phase 2 · NCT05534750
- Vaccination with conventional BCG (BCG-WT)Phase 2 · NCT07762014
- Vaccination with rBCG-N-RSVPhase 2 · NCT07762014
- 3HPPhase 1/2 · NCT05122767
- BNT164a1Phase 1/2 · NCT05547464
- BNT164b1Phase 1/2 · NCT05547464
- DolutegravirPhase 1/2 · NCT06281834 · NCT07124559 · NCT05122767
- Ad5-105KPhase 1 · NCT06732583
- BCG-PPDPhase 1 · NCT04538911
- CAF®10bPhase 1 · NCT06050356
- Full dose intranasal H107ePhase 1 · NCT06050356
- H107ePhase 1 · NCT06050356
- H107e/CAF®10bPhase 1 · NCT06050356
- H107e/CAF®10b - full adjuvant dosePhase 1 · NCT06050356
- H107e/CAF®10b - low adjuvant dosePhase 1 · NCT06050356
- i.d. placeboPhase 1 · NCT06050356
- i.m. placeboPhase 1 · NCT06050356
- Intranasal H107ePhase 1 · NCT06050356
- ItraconazolePhase 1 · NCT06701136
- Itraconazole (200 mg)Phase 1 · NCT07883226
- LipovaksinS4-EAH (High Dose)Phase 1 · NCT07647107
- LipovaxinS4-EAH (Middle Dose)Phase 1 · NCT07647107
- Low dose intranasal H107ePhase 1 · NCT06050356
- MicrogynonPhase 1 · NCT07784894
- MK-8527Phase 1 · NCT07600775
- N Acetyl CysteinePhase 1 · NCT07058090
- QTP101Phase 1 · NCT06714513
- Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)Phase 1 · NCT07058090
- Rifampicin 600mgPhase 1 · NCT07883226
- Silymarin 420 mgPhase 1 · NCT07058090
- TBD11 (300 mg)Phase 1 · NCT07883226
- TBD11 (50 mg)Phase 1 · NCT07883226
- TBD11 (up to 300 mg)Phase 1 · NCT07883226
- Tuberculosis (TB) vaccine (Ad5-105K)Phase 1 · NCT06732583
- VIR-1778 (5 × 10^5 ffu)Phase 1 · NCT07818824
- VIR-1778 (5 × 10^6 ffu)Phase 1 · NCT07818824
- [18F]-FAPI-74Early phase 1 · NCT07830771
- Antituberculosis drugs GroupEarly phase 1 · NCT07875322
- Yiqi Gubiao pillEarly phase 1 · NCT06676800
- Yiqi Gubiao Pill placeboEarly phase 1 · NCT06676800
Closest to patients
- Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)People's Hospital of Zhuji, Zhejiang Province · Zhuji, China + 5 more hospitalsPhase 2/3Primary completion 2024
- DeMONSTRATE-TB Study in EthiopiaDeMONSTRATE-TB Study in EthiopiaBoloso Bombe woreda · Wolayita Zone, Ethiopia + 1 more hospitalPhase 2/3Primary completion 2025
- Novel Triple-dose Tuberculosis Retreatment RegimenNovel Triple-dose Tuberculosis Retreatment RegimenDamien Foundation · Niamey, NigerPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment.
Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment.
Molecular pharmaceutics
PubMed · PMID 42969738Publication
Maleylated-BSA-Coated Gold Nanopopcorns for Pulmonary Delivery of Quercetin.
Maleylated-BSA-Coated Gold Nanopopcorns for Pulmonary Delivery of Quercetin.
International journal of molecular sciences
PubMed · PMID 42884052Publication
Association of Vitamin D Receptor Gene Polymorphism (FokI) with Susceptibility to Musculoskeletal Tuberculosis: A Case-Control Study from Central India.
Association of Vitamin D Receptor Gene Polymorphism (FokI) with Susceptibility to Musculoskeletal Tuberculosis: A Case-Control Study from Central India.
Journal of orthopaedic case reports
PubMed · PMID 42713054
Find fellow researchers
Groups with active Tuberculosis work.
Stellenbosch University
Stellenbosch, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it
London School of Hygiene & Tropical Medicine
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Makerere University
Kampala, Uganda
Team details appear once the team leader joins.
Is this your team? Claim it
University of the Witwatersrand
Johannesburg, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
All India Institute of Medical Sciences
New Delhi, India
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, San Francisco
San Francisco, United States
Team details appear once the team leader joins.
Is this your team? Claim it
South African Medical Research Council
Cape Town, South Africa
Team details appear once the team leader joins.
Is this your team? Claim it